175 related articles for article (PubMed ID: 21436672)
61. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
[TBL] [Abstract][Full Text] [Related]
62. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.
Eltawil KM; Renfrew PD; Molinari M
HPB (Oxford); 2012 Apr; 14(4):260-8. PubMed ID: 22404265
[TBL] [Abstract][Full Text] [Related]
63. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Hammel P; Fabienne P; Mineur L; Metges JP; Andre T; De La Fouchardiere C; Louvet C; El Hajbi F; Faroux R; Guimbaud R; Tougeron D; Bouche O; Lecomte T; Rebischung C; Tournigand C; Cros J; Kay R; Hamm A; Gupta A; Bachet JB; El Hariry I
Eur J Cancer; 2020 Jan; 124():91-101. PubMed ID: 31760314
[TBL] [Abstract][Full Text] [Related]
64. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Richards DA; Kuefler PR; Becerra C; Wilfong LS; Gersh RH; Boehm KA; Zhan F; Asmar L; Myrand SP; Hozak RR; Zhao L; Gill JF; Mullaney BP; Obasaju CK; Nicol SJ
Invest New Drugs; 2011 Feb; 29(1):144-53. PubMed ID: 19714296
[TBL] [Abstract][Full Text] [Related]
65. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
66. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Meyer F; Lueck A; Hribaschek A; Lippert H; Ridwelski K
Chemotherapy; 2004 Dec; 50(6):289-96. PubMed ID: 15608445
[TBL] [Abstract][Full Text] [Related]
67. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
68. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
[TBL] [Abstract][Full Text] [Related]
69. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
[TBL] [Abstract][Full Text] [Related]
70. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.
Banu E; Banu A; Fodor A; Landi B; Rougier P; Chatellier G; Andrieu JM; Oudard S
Drugs Aging; 2007; 24(10):865-79. PubMed ID: 17896834
[TBL] [Abstract][Full Text] [Related]
71. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
72. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M
J Clin Oncol; 2019 Jan; 37(3):230-238. PubMed ID: 30523758
[TBL] [Abstract][Full Text] [Related]
73. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers.
Klapdor R; Seutter E; Lang-Pölckow EM; Reichle H; Hinrichs A
Anticancer Res; 1999; 19(4A):2459-69. PubMed ID: 10470175
[TBL] [Abstract][Full Text] [Related]
74. [Meta-analysis of the efficacy between gemcitabine-alone and gemcitabine-based chemotherapy applied in advanced pancreatic cancer].
Song K; Li B; Sun WJ
Zhonghua Wai Ke Za Zhi; 2011 Sep; 49(9):839-42. PubMed ID: 22177442
[TBL] [Abstract][Full Text] [Related]
75. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Stathopoulos GP; Syrigos K; Aravantinos G; Polyzos A; Papakotoulas P; Fountzilas G; Potamianou A; Ziras N; Boukovinas J; Varthalitis J; Androulakis N; Kotsakis A; Samonis G; Georgoulias V
Br J Cancer; 2006 Sep; 95(5):587-92. PubMed ID: 16909140
[TBL] [Abstract][Full Text] [Related]
76. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.
Schneider BP; Ganjoo KN; Seitz DE; Picus J; Fata F; Stoner C; Calley C; Loehrer PJ
Oncology; 2003; 65(3):218-23. PubMed ID: 14657595
[TBL] [Abstract][Full Text] [Related]
77. Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Corrie P; Mayer A; Shaw J; D'Ath S; Blagden S; Blesing C; Price P; Warner N
Br J Cancer; 2002 Sep; 87(7):716-9. PubMed ID: 12232752
[TBL] [Abstract][Full Text] [Related]
78. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
[TBL] [Abstract][Full Text] [Related]
79. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Yip D; Karapetis C; Strickland A; Steer CB; Goldstein D
Cochrane Database Syst Rev; 2006 Jul; (3):CD002093. PubMed ID: 16855985
[TBL] [Abstract][Full Text] [Related]
80. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Spry N; Harvey J; Macleod C; Borg M; Ngan SY; Millar JL; Graham P; Zissiadis Y; Kneebone A; Carroll S; Davies T; Reece WH; Iacopetta B; Goldstein D
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1438-46. PubMed ID: 18164859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
